Promosyon programı Aura Biosciences, Inc.
Gelişmiş program
Basit grafik
Şirket hakkında Aura Biosciences, Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. daha fazla ayrıntı| IPO date | 2021-10-29 |
|---|---|
| ISIN | US05153U1079 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.aurabiosciences.com |
| Цена ао | 5.99 |
| Günlük fiyat değişimi: | 0% (5.45) |
|---|---|
| Haftalık fiyat değişimi: | +4.21% (5.23) |
| Aylık fiyat değişimi: | -25.85% (7.35) |
| 3 ayda fiyat değişimi: | -27.91% (7.56) |
| Altı ayda fiyat değişimi: | -46.83% (10.25) |
| Yıllık fiyat değişimi: | -24.93% (7.26) |
| 3 yılda fiyat değişimi: | -68.13% (17.1) |
| Yılbaşından bu yana fiyat değişimi: | -34.65% (8.34) |
|
|
Hafife alma
|
Yeterlik
|
|||||||||||||||||||||||||||||||||||||
Temettüler
|
Görev
|
Büyüme dürtüsü
|
|||||||||||||||||||||||||||||||||||||
| Kurumlar | Hacim | Paylaşmak, % |
|---|---|---|
| Matrix Capital Management | 6922870 | 13.98 |
| Eventide Asset Management LLC | 5802682 | 11.72 |
| Adage Capital Partners GP L.L.C. | 4225000 | 8.53 |
| Citadel Advisors Llc | 3631294 | 7.34 |
| Medicxi Ventures Management (Jersey) Ltd | 3039892 | 6.14 |
| Nantahala Capital Management, LLC | 2643720 | 5.34 |
| Blackrock Inc. | 2098745 | 4.24 |
| Vanguard Group Inc | 1730431 | 3.5 |
| Decheng Capital Management III (Cayman), LLC | 1163123 | 2.35 |
| Goldman Sachs Group Inc | 1037299 | 2.1 |
| Süpervizör | İş unvanı | Ödeme | Doğum yılı |
|---|---|---|---|
| Dr. Elisabet de los Pinos Ph.D. | Founder, CEO, President & Director | 895.16k | 1974 (51 yıl) |
| Ms. Julie B. Feder | Chief Financial Officer | 604.2k | 1971 (54 yıl) |
| Dr. Mark Plavsic D.V.M., Ph.D. | Chief Technology Officer | N/A | 1961 (64 yıl) |
| Mr. Patrick Nealon | Senior Vice President of Clinical Development Operations | N/A | |
| Dr. Anthony Daniels M.D. | Therapeutic Area Head of Ocular Oncology | N/A | |
| Dr. Richard Mountfield Ph.D. | Senior Vice President of Regulatory Affairs & Quality | N/A | |
| Mr. Conor Kilroy | General Counsel & Secretary | N/A | 1982 (43 yıl) |
| Dr. Jill J. Hopkins M.D. | Chief Medical Officer & President of Research and Development | N/A | 1965 (60 yıllar) |
Adres: United States, Boston. MA, 80 Guest Street - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.aurabiosciences.com
Web sitesi: https://www.aurabiosciences.com
